. Author manuscript; available in PMC: 2020 Jan 1.

Published in final edited form as: J Frailty Aging. 2019;8(3):154–159. doi: 10.14283/jfa.2018.45

Table 4.

Bivariate and Multivariate Linear Regression Exploring the Effects of Tesamorelin Compared to Placebo on Changes in Muscle Density (Hounsfield Units [HU]) and Muscle Area (cm²)

	Total Muscle Density (top) or Area (bottom)			Lean Muscle Density (top) or Area (bottom)
	Tesamorelin Effect Compared to Placebo (baseline adjustment only)	Tesamorelin Effect, Adjusted for Baseline and Change in VAT or IGF-1		Tesamorelin Effect Compared to Placebo (baseline adjustment only)	Tesamorelin Effect, Adjusted for Baseline and Change in VAT or IGF-1
	Coefficient (SE)			Coefficient (SE)
		Δ VAT^†	Δ IGF-1^†		Δ VAT^†	Δ IGF-1^†
Muscle Density (HU)
Anterolateral/abdominal	2.98 (0.51)^***	1.32 (0.58)^*	2.77 (0.62)^***	1.39 (0.32)^***	0.55 (0.41)	1.29 (0.41)^***
Rectus	4.86 (0.83)^***	3.10 (1.09)^***	4.41 (1.05)^***	1.78 (0.48)^***	1.29 (0.63)^*	1.59 (0.74)^*
Psoas	1.56 (0.37)^***	0.74 (0.45)	1.23 (0.52)^*	0.82 (0.30)^**	0.40 (0.35)	0.85 (0.41)^*
Paraspinal	1.97 (0.38)^***	1.58 (0.51)^***	1.93 (0.55)^***	0.51 (0.25)^*	0.47 (0.33)	0.58 (0.37)
Muscle Area (cm²)
Anterolateral/abdominal	−0.11(0.31)	1.23 (0.42)^***	−0.25 (0.41)	1.08 (0.31)^***	1.38 (0.37)^***	0.91 (0.38)^*
Rectus	0.44 (0.15)^***	0.57 (0.20)^***	0.32 (0.19)	0.85 (0.15)^***	0.75 (0.21)^***	0.69 (0.20)^***
Psoas	0.46 (0.12)^***	0.62 (0.16)^***	0.27 (0.19)	0.64 (0.13)^***	0.66 (0.17)^***	0.38 (0.19)^*
Paraspinal	0.46 (0.22)^*	0.97(0.28)^***	0.24 (0.25)	0.96 (0.23)^***	1.30 (0.30)^***	0.81 (0.28)^***

^***

p<0.005

^**

p<0.01

p<0.05

^†

multivariate model including baseline value of muscle area or density, treatment arm, and either change in visceral adipose tissue (VAT) area or change in insulin-like growth factor (IGF)-1.